McEwen Mining Q4 & 2022 Results Conference Call 8-03-2023, 23:15

Io Therapeutics, Inc., presented data from studies of IRX4204, the company’s phase II clinical development stage, highly selective third generation RXR nuclear receptor agonist compound, supporting its potential use for prevention and treatment of normal 10-07-2024, 07:00

Major Drilling Appoints New Operations Officers to Support 10-03-2023, 04:22